Exploring the effects of weight-loss and GLP-1 therapies, researchers determine the specific metabolic determinants that lead to patients’ weight reduction.
|Articles|September 6, 2013
VIDEO: Avoidable Costs in U.S. Healthcare
Doug Long, VP, Industry Relations, IMS Health, discusses the report: "Avoidable Costs in U.S. Healthcare: The $200 Billion Opportunity from Using Medicines More Responsibly."
Advertisement
Doug Long, VP, Industry Relations, IMS Health, discusses the report: "Avoidable Costs in U.S. Healthcare: The $200 Billion Opportunity from Using Medicines More Responsibly."
Advertisement
Related to this article
The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
Among patients with type 2 diabetes, researchers explore the effects of selecting additional therapy for GLP-1 treatment.
Adults with type 1 diabetes who used Omnipod 5 Automated Insulin Delivery System maintained significant improvements in time in range and hemoglobin A1C.
A Bayesian meta-analysis finds patients regain half their treatment-associated weight loss within about 7.5 months of stopping semaglutide or tirzepatide.
Once-weekly basal insulin has moved from an intriguing possibility to a new clinical reality.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
How the Main Street Pharmacy Access Act Advances Pharmacist Provider Status
3
Generic Drug Costs Burdening Patients as Much as Brand Name Options
4
COVID-19 Vaccine Hesitancy in 2026: How Attitudes Have Shifted
5